Ivarmacitinib (SHR0302) is a potent and orally active inhibitor of all members of the JAK family, particularly JAK1. It demonstrates selectivity for JAK1, being >10-fold more selective for JAK2, 77-fold for JAK3, and 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and promotes apoptosis in hepatic stellate cells, exhibiting anti-proliferative and anti-inflammatory properties.
- Potent and orally active JAK family inhibitor.
- Highly selective for JAK1.
- Inhibits JAK1-STAT3 phosphorylation.
- Induces apoptosis in hepatic stellate cells.
- Possesses anti-proliferative effects.
- Exhibits anti-inflammatory effects.